Table 3.
Priority | Investment Level Change as “Postdeliberation Minus Predeliberation” | Changeb (p‐value) | ||||||
---|---|---|---|---|---|---|---|---|
Lower Level at Postdeliberation | Higher Level at Postdeliberation | |||||||
−3 | −2 | −1 | 0a | 1 | 2 | 3 | ||
Causes of Disease | 9 (5.4) | 13 (7.8) | 25 (15.0) | 75 (44.9) | 23 (13.8) | 17 (10.2) | 5 (3.0) | −.04 (.73) |
New approaches | 11 (6.6) | 23 (13.8) | 38 (22.8) | 54 (32.3) | 21 (12.6) | 10 (6.0) | 10 (6.0) | −.28 (.05) |
Promote Health | 2 (1.2) | 12 (7.2) | 29 (17.4) | 75 (44.9) | 30 (18.0) | 17 (10.2) | 2 (1.2) | .07 (.45) |
Compare Approaches | 2 (1.2) | 10 (6.0) | 25 (15.0) | 74 (44.3) | 39 (23.4) | 10 (6.0) | 7 (4.2) | .17 (.06) |
Patient‐Doctor | 3 (1.8) | 11 (6.6) | 21 (12.6) | 71 (42.5) | 44 (26.4) | 14 (8.4) | 3 (1.8) | .17 (.05) |
Quality of Life | 8 (4.8) | 11 (6.6) | 28 (16.8) | 79 (47.2) | 25 (15.0) | 7 (4.2) | 9 (5.4) | −.05 (.60) |
Health Inequity | 7 (4.2) | 15 (9.0) | 20 (12.0) | 71 (42.5) | 35 (21.0) | 14 (8.4) | 5 (3.0) | .04 (.72) |
Multiple Conditions | 9 (4.8) | 16 (9.6) | 32 (19.2) | 65 (38.9) | 26 (15.6) | 14 (8.4) | 6 (3.6) | −.10 (.37) |
Special Needs | 3 (1.8) | 9 (5.4) | 31 (18.6) | 64 (38.3) | 37 (22.2) | 16 (9.6) | 7 (4.2) | .19 (.07) |
Families/Caregivers | 6 (3.6) | 9 (5.4) | 21 (12.6) | 64 (38.3) | 36 (21.6) | 17 (10.2) | 14 (8.4) | .33 (.03) |
Access | 6 (3.6) | 9 (5.4) | 28 (16.8) | 59 (35.3) | 28 (16.8) | 17 (10.2) | 20 (12.0) | .35 (.01) |
Improve Research | 7 (4.2) | 13 (7.8) | 27 (16.2) | 64 (38.3) | 40 (24.0) | 7 (4.2) | 9 (5.4) | .04 (.68) |
Rare Diseases | 5 (3.0) | 12 (7.2) | 19 (11.4) | 69 (41.3) | 40 (24.0) | 19 (11.4) | 3 (1.8) | .17 (.07) |
Includes those who did not select the priority at both rounds.
Mean change in the investment level, where the change is calculated as after deliberation level minus before deliberation level; positive values correspond to higher investment level selection after deliberation, and p‐values are adjusted for within‐CHAT group clustering using multilevel regression model.